Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2024; 30(35): 3965-3971
Published online Sep 21, 2024. doi: 10.3748/wjg.v30.i35.3965
Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver disease
Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Ashok Iyaswamy
Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur 610005, India
Siva Sundara Kumar Durairajan, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong 999077, China
Ashok Iyaswamy, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China
Ashok Iyaswamy, Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore 641021, India
Co-first authors: Siva Sundara Kumar Durairajan and Abhay Kumar Singh.
Author contributions: Singh AK and Iyaswamy A reviewed the literature; Durairajan SSK conceived the idea and coordinated the manuscript; Durairajan SSK and Singh AK drafted the manuscript and approved the final version of the article, and as such merit co-first authorship of this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Siva Sundara Kumar Durairajan, MSc, PhD, Associate Professor, Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Neelakudi, Tiruvarur 610005, India. d.sivasundarakumar@cutn.ac.in
Received: July 18, 2024
Revised: August 11, 2024
Accepted: August 26, 2024
Published online: September 21, 2024
Processing time: 56 Days and 17.4 Hours
Core Tip

Core Tip: Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors, including PPARα, PPARγ, and PPARβ/δ. They regulate vital factors in the development of alcoholic liver disease (ALD), like lipid metabolism, inflammation, and fibrosis. PPAR agonists have the potential to manage ALD. In recent preclinical and clinical trials, PPAR agonists have revealed their potency to eliminate liver steatosis, improve insulin receptor sensitivity, and diminish inflammation and fibrosis. However, to confirm their effectiveness and reveal side effects, larger clinical trials in ALD must be conducted. This article, therefore, raises the need for further study and debate on the application of PPAR agonists for ALD management.